WASHINGTON, D.C.—Epilepsy-related deaths are a significant public health problem, yet are poorly understood and often overlooked. People with epilepsy are two to three times more likely to die prematurely than people without the disease. The greatest cause of epilepsy-related deaths, Sudden Unexpected Death in Epilepsy (SUDEP), kills more than 1 out of 1,000 people with epilepsy each year in the U.S. When seizures are uncontrolled, the risk of SUDEP increases to more than 1 out of 150.
CURE To Expand Work With Veterans’ Epilepsy Thanks To Department Of Defense Grant
Chicago, IL- Citizens United for Research in Epilepsy today announced that it will create a new research program and focus with a grant of approximately 10 million dollars over 5 years to go toward epilepsy research in veterans with traumatic brain injury. The grant was awarded by the Department of Defense, Psychological Health and Traumatic Brain Injury Research Program, award number W81XWH-15-2-0069.
The grant will support a team approach to researching the prevention and treatment of Post-Traumatic Epilepsy (PTE). The incidence of epilepsy in active service members increased by an alarming 52 percent from 2006 to 2010. Approximately 8 percent of those afflicted have been diagnosed with traumatic brain injury (TBI) , making it the most common predisposing condition. Twenty-four percent of military-related epilepsy is associated with prior TBI.
“Our veterans deserve much better after serving our country,” said Susan Axelrod, founding chair of CURE. “In the wars in Iraq and Afghanistan the “signature wound” was traumatic brain injury. Those who suffer severe TBI face up to a 50 percent chance of developing Post-Traumatic Epilepsy (PTE), with the symptoms of epilepsy (seizures) manifesting themselves immediately or even up to fifteen years post-injury. At CURE we are committed to exploring the complex underlying mechanisms of post-traumatic epilepsy and ways to treat it more effectively and one day even prevent it entirely.”
Johns Hopkins Epilepsy Study Is First Researchkit App to Use Apple Watch
EpiWatch is an epilepsy research study that monitors seizure symptoms with Apple Watch to improve seizure detection, improve medication adherence and enhance quality of life for those who suffer from seizures.
Today, Johns Hopkins researchers introduced EpiWatch, designed to use Apple Watch to collect patient data through the open source ResearchKit framework designed by Apple. The app, which runs on Apple Watch and iPhone, collects data from patients with epilepsy before, during and after their seizures.
Over 2.5 million people are living with epilepsy in the United States. The data gathered by the app, including physiological changes, altered responsiveness and other characteristics of recurrent seizures, will be used by researchers to better understand epilepsy and to develop new methods for monitoring and managing the disease and the role of technology.
One morning, about 20 years ago, Tracy Dixon-Salazar heard a strange sound coming from her daughter’s bedroom. She rushed in to find 2-year-old Savannah jerking violently in bed, apparently choking. But when the paramedics came, they couldn’t find an obstruction or anything else to cause her condition.
“No one could explain why I had a healthy 2-year old one day and the next day that was gone,” Tracy says.
Savannah was having seizures caused by a severe form of epilepsy called Lennox-Gastaut syndrome (LGS). LGS seizures typically start before age 4, according to the National Institute of Neurological Disorders and Stroke, and there are many types. Most LGS patients experience frequent seizures that do not respond to current epilepsy therapies. And they often have memory problems, learning deficits, developmental delays and behavioral issues.
For two-thirds of people with all forms of epilepsy, including Savannah, the cause is unknown. Treatment is even more challenging.
Study aims to determine etiology, clinical features and predictors of outcome of new-onset refractory status epilepticus
Objectives: The aims of this study were to determine the etiology, clinical features, and predictors of outcome of new-onset refractory status epilepticus.
Methods: Retrospective review of patients with refractory status epilepticus without etiology identified within 48 hours of admission between January 1, 2008, and December 31, 2013, in 13 academic medical centers. The primary outcome measure was poor functional outcome at discharge (defined as a score .3 on the modified Rankin Scale).
BLUE ASH, Ohio, August 3, 2015 – Aprecia Pharmaceuticals Company today announced that the U.S. Food and Drug Administration (FDA) has approved SPRITAM® levetiracetam for oral use as a prescription adjunctive therapy in the treatment of partial onset seizures, myoclonic seizures and primary generalized tonic-clonic seizures in adults and children with epilepsy. SPRITAM utilizes Aprecia’s proprietary ZipDose® Technology platform, a groundbreaking advance that uses three-dimensional printing (3DP) to produce a porous formulation that rapidly disintegrates with a sip of liquid.1 While 3DP has been used previously to manufacture medical devices, this approval marks the first time a drug product manufactured with this technology has been approved by the FDA.
“By combining 3DP technology with a highly-prescribed epilepsy treatment, SPRITAM is designed to fill a need for patients who struggle with their current medication experience,” said Don Wetherhold, Chief Executive Officer of Aprecia. “This is the first in a line of central nervous system products Aprecia plans to introduce as part of our commitment to transform the way patients experience taking medication.”
NIH Names Walter J. Koroshetz, M.D. Director of the National Institute of Neurological Disorders and Stroke
National Institutes of Health Director Francis S. Collins, M.D., Ph.D., announced today the selection of Walter J. Koroshetz, M.D., as the Director of the National Institute of Neurological Disorders and Stroke (NINDS). He has served as Acting Director of the NINDS since October, 2014.
I am very pleased that Dr. Koroshetz has accepted the enormous responsibility of being the NINDS Director,” said Dr. Collins. “His deep grounding in clinical neurology and basic neuroscience research makes him the ideal candidate to lead NINDS into the future and to fulfill the Institute’s mission to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.”
In announcing the appointment, Dr. Collins recognized Dr. Koroshetz’ role in the creation of the StrokeNet, a national clinical trial network for research in stroke treatment, prevention, and recovery as well as his role as point person for traumatic brain injury research at the NIH, and Co-founder of the NIH-Uniformed Services Center for Neuroscience and Regenerative Medicine (TBI research center).
Initiative seeks to uncover causes, develop treatments, design possible cures for epilepsies
Three million Americans have some form of epilepsy; in 68 percent of the cases the cause remains unknown. More than a third of patients with uncontrollable seizures are not effectively treated with current therapies, which are often prescribed on a trial-and-error basis.
Now, the Epilepsy Genetic Initiative will offer a project to uncover the causes, develop precision treatments, and design possible cures for epilepsies at Children's Hospital of Philadelphia and seven other academic medical centers.
The initiative was created in partnership with the Citizens United for Research in Epilepsy (CURE) and the National Institute of Neurological Disorders and Stroke, and is sponsored by the John and Barbara Vogelstein Foundation.
"One in three patients don't respond to treatments," said Tracy Dixon-Salazar, program officer and associate research director of CURE. "We're not making a dent in the most severe patients. We've been targeting seizures, not the cause of the disease. By identifying what syndrome is causing a particular epilepsy and treating that cause, we will change treatments."
First-of-its-Kind Initiative Aims to Unlock the Genetic Secrets of Epilepsy
April 27, 2015, CHICAGO – Three million Americans currently live with epilepsy and 30-40 percent have uncontrollable seizures – of which genetics is proving to be a major cause. Citizens United for Research in Epilepsy (CURE) today announced the launch of its new signature program, the Epilepsy Genetics Initiative (EGI) – a first-of-its-kind database for epilepsy that aims to unlock the genetic secrets of the disease, driving research into its causes and treatments to ultimately find a cure for epilepsy.
The John and Barbara Vogelstein Foundation is the principal sponsor of EGI, having generously committed $1 million to the project over 3 years. "We think that genetics are the next frontier for epilepsy treatment," said John Vogelstein. "We know firsthand how devastating epilepsy can be. We're confident that with CURE's leadership, EGI can provide families with answers, and researchers with the tools to find a cure."
For patients diagnosed with epilepsy, initial analysis of their DNA may not identify a cause for the disease. EGI will permit for reanalysis as breakthrough genetic discoveries are made, linking patients, physicians and scientists together to better customize treatment for different forms of epilepsy.
CURE is Proud to Support 2015 HHMI Medical Research Fellow Kun Wei Song of Duke University!
HHMI has selected 68 top medical and veterinary students from 37 different schools in the United States to conduct full-time biomedical research in its Medical Research Fellows Program. The $2.8 million annual initiative is designed to develop the next generation of physician-scientists by giving the students a full year of mentored research training with some of the nation’s top biomedical scientists.
This year, five physician-scientists who are program alumni will serve as mentors to medical fellows in the new class. One of those mentors, Daphne Haas-Kogan, was a member of the inaugural class of Medical Research Fellows in 1989. “Given the mentorship I received as an HHMI Medical Fellow, I cannot imagine a career that did not revolve around being a mentor to future physician-scientists,” said Haas-Kogan, who is now a professor of Radiation Oncology and Neurological Surgery at the University of California, San Francisco. In July, she will become chair of the department of Radiation Oncology at Dana-Farber/Brigham and Women’s Cancer Center, and a professor at Harvard Medical School.
Sudden death in epilepsy: Researchers finger possible cause
Sudden death, a mysterious and devastating outcome of epilepsy, could result from a brain stem shutdown following a seizure, researchers report today in Science Translational Medicine. Although the idea is still preliminary, it’s engendering hope that neurologists are one step closer to intervening before death strikes.
Sudden unexpected death in epilepsy (SUDEP) has long bedeviled doctors and left heartbroken families in its wake. “It’s as big a mystery as epilepsy itself,” says Jeffrey Noebels, a neurologist at Baylor College of Medicine in Houston, Texas, and the senior author of the new paper. As its name suggests, SUDEP attacks without warning: People with epilepsy are found dead, often following a seizure, sometimes face down in bed. Many are young—the median age is 20—and patients with uncontrolled generalized seizures, the most severe type, are at highest risk. About 3000 people are thought to die of SUDEP each year in the United States. And doctors have struggled to understand why. “How can you have seizures your whole life, and all of a sudden, it’s your last one?” Noebels asks.
In 2013, an international team of researchers described its study of epilepsy patients who had died while on hospital monitoring units. In 10 SUDEP cases for which they had the patients’ heart function and breathing patterns, the authors found that the patients’ cardiorespiratory systems collapsed over several minutes, and their brain activity was severely depressed. “Their EEG went flat after a seizure,” says Stephan Schuele, an epileptologist at Northwestern University Feinberg School of Medicine in Chicago, Illinois, who wasn’t involved in the study.
UCB leads epilepsy hackathon to support patient needs through digital tools and services
Brussels (Belgium), 18th February 2015– 0700 (CET) – UCB today announced that it will sponsor a two-city epilepsy hackathon – ‘Hack Epilepsy’ - with a single purpose to improve the lives of people living with epilepsy. The hackathon will be held simultaneously in Brussels, Belgium, and Atlanta, US, on the 24th -26th April 2015, and is expected to attract developers, designers and digital experts.
“Epilepsy affects millions of people all over the world. At UCB, we want to support patients, their families and caregivers, with digital solutions that can connect them to valuable sources of knowledge and experience that can make a meaningful difference to their day-to-day living,” said Erik Janssen, Vice President Global Patient Solutions Epilepsy, UCB. “Hackathons are rapidly establishing themselves as a fast, effective way to develop innovative digital healthcare solutions. Creative, highly skilled online developers and designers relish the challenge of coming up with practical, workable prototypes that can be of real value to people with a severe disease such as epilepsy.”
Speakers: Kelly Knupp, MD
Children’s Hospital Colorado
Ben Whalley, PhD
Professor of Neuropharmacology
Director or Research, School of Pharmacy
University of Reading, UK
Have you heard about medical cannabis or cannabidol (CBD) as a potential treatment option for people with epilepsy and wondered if it could help your family? Do you want to learn more about how families may gain access to this potential treatment option? Are you curious about the experiences of families who have gained access? If so, you don’t want to miss this webinar.
During this webinar Dr. Kelly Knupp will discuss clinical studies on medical cannabis and what they have taught us. She will explain the potential risks associated with CBD use and the legal issues that have arisen in Colorado. Dr. Ben Whalley will review the existing research on the therapeutic effects and safety of cannabis. Our panelists will share personal experiences with CBD use, the realities of moving to a new state to gain access to this treatment option, how state and federal laws limit or allow access to this treatment option, the important role of research, and the process by which potential treatments gain Food and Drug Administration (FDA) approval.
Association of prone position with sudden unexpected death in epilepsy
Objective: To examine the association between prone position and sudden unexpected death in epilepsy (SUDEP).
Methods: We conducted a systematic review and meta-analysis based on a literature search from databases PubMed, Web of Science, and Scopus, using keywords “SUDEP” or “sudden unexpected death in epilepsy” or “sudden unexplained death syndromes in epilepsy.” Twenty-five publications met the inclusion and exclusion criteria and were enrolled in this study.
Conclusion: There is a significant association between prone position and SUDEP, which suggests that prone position is amajor risk factor for SUDEP, particularly in patients aged 40 years and younger. As such, SUDEP may share mechanisms similar to sudden infant death syndrome.
The second Partners Against Mortality in Epilepsy conference took place in Minneapolis, Minnesota, on June 19–22, 2014. Presenters summarized the latest research on death in people with epilepsy, especially sudden unexpected death in epilepsy (SUDEP). SUDEP is a death that is sudden and unexpected and that isn’t due to an injury, drowning, or another known cause. The audience included people who had lost a loved one to SUDEP, those living with epilepsy, families of people with epilepsy, doctors, nurses, basic and clinical scientists, and representatives of advocacy and research organizations.
In addition to the topics presented at the first Partners Against Mortality in Epilepsy in 2012, the 2014 meeting focused on major causes of death in people with epilepsy other than SUDEP, grief related to epilepsy, how often SUDEP happens, and guidelines for health-care providers. Speakers included some of the most prominent scientists in the field.
The conference included several plenary sessions designed to be easily understood by attendees with different levels of scientific knowledge and experiences with epilepsy. Attendees also joined small discussion groups offering in-depth reviews of certain scientific topics.
OU Children's Hospital Hosts Annual Isaiah Stone Pediatric Epilepsy Lecture Series
OKLAHOMA CITY – The Isaiah Stone Foundation is sponsoring the third annual Isaiah Stone Pediatric Epilepsy Lecture Series from 5:30 – 7 p.m. on Feb. 3 at the OU Children’s Hospital. Dr. Eric Kossoff, Professor of Neurology and Pediatrics at Johns Hopkins University School of Medicine, will join in a panel discussion with several of the country’s leading pediatric epileptologists. The event is free to the public, and parents and caregivers of children with epilepsy are encouraged to attend.
“This is a great opportunity for parents and caregivers to learn more about how to care for their loved one and the many advances happening in the treatment of epilepsy,” said Renzi Stone, founder of the Isaiah Stone Foundation and Chairman and CEO of Saxum. The event is supported by an education grant from Eisai, Inc., The Anschutz Family Foundation, Supernus Pharmaceuticals and Lundbeck.
NINDS Announcement of Center Without Walls Signals Onset of Exciting Period in Epilepsy Research
The creation of a virtual Center Without Walls to study sudden unexpected death in epilepsy (SUDEP) was announced by the US National Institute of Neurological Disorders and Stroke (NINDS) on Dec 8, 2014. For the epilepsy community—at that time gathered in Seattle, WA, USA, for the Annual Meeting of the American Epilepsy Society—the announcement of this new initiative signals the onset of an exciting period in epilepsy research. Large collaborative research initiatives are needed to shed light on the risk factors and mechanisms that can lead from epilepsy to premature death, and the creation of this new Center Without Walls will accelerate progress over the coming year.
Nine research teams form the new Center Without Walls, with a budget of less than US$6 million at present. Investigators will share data and resources to address SUDEP from several angles: from the study of underlying brainstem pathways to the associated respiratory and cardiac dysfunction, and from neuropathological analyses to the assessment of genetic susceptibility. NINDS should be commended for prioritising this area of epilepsy research. The risk of sudden death is about 20-times higher in people with epilepsy than in the general population. Incidence ranges from 0·09 per 1000 person-years in newly diagnosed patients to 9·3 per 1000 person-years in candidates for epilepsy surgery. However, sudden death is a major concern not only in people with pharmacologically intractable epilepsy (who have an estimated 35% lifetime risk), but also in adult patients in whom epilepsy is not fully controlled, in patients with predisposing mutations, and in children with Dravet syndrome. In the USA alone, there are about 3000 cases of SUDEP each year. Understanding the genetic, physiological, and environmental risk factors behind such increased mortality will lead to preventive strategies that can help to tackle these dismal figures.
NIH initiates "Centers Without Walls" to study sudden unexpected death in epilepsy
Since encouraging research into SUDEP more than a decade ago and funding our first grant in 2004, CURE is pleased to announce the launch of the first-ever SUDEP Center Without Walls, funded by National Institute of Neurological Disorders and Stroke.
Nearly $6M has been allocated for this virtual research center in 2014, of which much will go toward projects led by CURE Grantees. We are also thrilled that Dr. Vicky Whittemore, a key member of our Scientific Advisory Council, will be part of the leadership of the Center.
CURE's HHMI Fellow Abhijeet Gummadavelli is Lead Author on Paper About Consciousness and Seizures
Loss of consciousness is a common and dangerous side effect of epileptic seizures. A new Yale-led study, however, shows that activation of electrodes in key brain areas can awaken rats with induced seizures.
“At least a quarter of people with epilepsy have seizures that can’t be controlled,” said Dr. Hal Blumenfeld, professor of neurology, neurobiology, and neurosurgery, and senior author of the study. “Our hope is that for this population, brain stimulation can help reduce injuries and deaths that result from a loss of consciousness.”
CDC's Morbidity and Mortality Weekly Report (MMWR) Addresses Mortality and Co-Occurring Conditions with Pediatric Epilepsy
Epilepsy is a common childhood neurologic disorder. In 2007, epilepsy affected an estimated 450,000 children aged 0–17 years in the United States. Approximately 53% of children with epilepsy and special health care needs have co-occurring conditions, and only about one third have access to comprehensive care. The few studies of mortality risk among children with epilepsy as compared with the general population generally find a higher risk for death among children with epilepsy with co-occurring conditions but a similar risk for death among children with epilepsy with no co-occurring conditions.
It's Epilepsy Awareness Month! Learn more about how epilepsy affects kids.
The term epilepsy is a broad term used for conditions that affect the brain and cause recurring seizures. More than 450,000 children have epilepsy in the United States Picture a school with 1,000 students—that means at least 6 students would have epilepsy.
A CDC study showed that students aged 6–17 years with epilepsy were more likely to miss 11 or more days of school in the past year compared with students who had health concerns other than epilepsy. Also, students with epilepsy were found to be more likely to have difficulties in school, use special education services, and have activity limitations such as less participation in sports or clubs.
JEANNE PAZ SAT in the dim light of the basement laboratory, staring intensely at her research subject. The rat took little notice, and continued nosing about the bedding of his cage. Paz checked the EEG monitor, watching the waves of electrical activity coming from the rodent's brain. Suddenly, the once wobbly waveform began to spike rapidly, becoming a dense forest of zigzag lines.
Even to an untrained eye it would have been obvious that the rat's brain was acting very strangely. To Paz, it was a clear sign of an epileptic attack. Indeed, the rat was no longer casually exploring his enclosure, but was struck motionless, frozen in a corner of his cage. After nearly a minute, the wild spiking of the EEG signal tapered off, and the rat relaxed, returning to his normal rodent business.
A few minutes later, the EEG signal began to spike again with the onset of another attack. This time, however, Paz flipped a nearby switch, and the epilepsy-like activity resolved instantly. The rat seemed unaware that anything out of the ordinary was happening, but Paz felt the hairs on the back of her neck stand on end. "In French we call this chair de poule," Paz told me later. "Goose pimples."
NIH and CDC Announce Grantees for the Sudden Death in the Young Registry
The NIH and CDC announce awards to ten grantees for the Sudden Death in the Young Registry. Six are current or former grantees from the Sudden Unexpected Infant Death (SUID) Registry: Georgia, Michigan, Minnesota, New Hampshire, New Jersey, and Wisconsin. Four are new grantees: Delaware, Tennessee, the city of San Francisco and the Tidewater region of Virginia.
Grants were awarded on September 30, 2014. After a period of training and preparation, the grantees will begin reviewing cases in January 2015. After obtaining consent, information gathered through Child Death Review and advanced clinical review will be entered into a database managed by the Michigan Public Health Institute and DNA samples will be stored at a biorepository.
SIgn Up Now for the November 6 PAME Webinar on Rare Epilepsies
Have you or a loved one been diagnosed with a rare epilepsy including: Aicardi Syndrome, CDKL5 Disorder, Dravet Syndrome, Dup15q Syndrome, Hypothalamic Hamartoma, Lennox-Gastaut Syndrome, Ohtahara Syndrome, PCDH19 Female Epilepsy, Phelan-McDermid Syndrome or Tuberous Sclerosis Complex?
If so, you are not alone. Though each syndrome is different, patients and caregivers with rare epilepsies share many common seizures types, symptoms, and side effects.
During this webinar you will learn more about the rare epilepsies and the serious risks associated with these syndromes, including Sudden Unexpected Death in Epilepsy (SUDEP). You will be informed about the Rare Epilepsy Network (REN) and how it will help to identify better prevention and treatment options.
CURE Grantee Receives $1.5 Million NIH Grant to Continue Epilepsy Research
OMAHA, Nebraska -- The National Institute of Neurological Disorders and Stroke has awarded Timothy Simeone, Ph.D., a five-year $1.5 million National Institutes of Health (NIH) grant to identify new mechanisms in epilepsy to provide potential targets for future therapeutics.
Simeone is an assistant professor of Pharmacology in Creighton University’s School of Medicine. The study is related to his previous research, which has identified one particular protein important for the management of seizures in children and adolescents with a special high-fat diet. Simeone’s research will explore the role of this protein, and associated regulator pathways, in normal and epileptic brain function. He aims to determine previously unknown mechanisms of epilepsy and identify additional targets for therapeutic development.
The research is especially important because one in 26 people will develop epilepsy in their lifetime of which approximately 30 percent will not achieve adequate seizure control with current anti-seizure drugs. That same population is at greatest risk of sudden unexpected death in epilepsy (SUDEP).
CURE Grantee Published in the Journal of Neuroscience
Dr. Naegele transplanted new inhibitory cells into the brains of mice 2 weeks after an epilepsy-producing stimulus. As others have also reported, her group saw that the mice with the transplants had fewer and milder seizures compared to controls. This work went one step further than previous studies to look at the mechanism by which cell transplantation decreases seizures and found new inhibitory connections in a part of the brain known to contribute to seizures in temporal lobe epilepsy.
Chicago Bears GM Phil Emery Tackles Epilepsy Head-On as CURE's Newest Board Member
Chicago, IL - As general manager for the Chicago Bears, Phil Emery has watched his team face many difficult opponents on the football field. But no football team has dealt with the challenges that his 30-year-old daughter April has faced since being diagnosed with uncontrollable epilepsy at only 6-years-old.
Emery has decided to do something to help his daughter - and all of those who suffer from the devastating disease. On September 23, he was elected to the Board of Directors of Citizens United for Research in Epilepsy (CURE) the leading nonprofit organization dedicated to supporting research for a cure for epilepsy.
By Liane Kupferberg Carter
Reprinted with permission by The Chicago Tribune
Maybe it's just this time of year making me pensive. Summer is ending. Kids are leaving for college. Social media are crammed with articles and advice on how to weather the seismic family shift: "Get Your Heart and Mind Ready." "Loosen the Times That Bind." "How to Navigate What Comes Next."
My autistic son, Mickey, has finished high school. In our state, a developmentally disabled child "exits" the school system at 21. They call it "exiting" — not "graduating." He has "transitioned" — to a Byzantine, chronically underfunded system of government services for disabled adults. Mickey hasn't graduated, exactly. Neither have I.
This point was recently driven home when a woman in our neighborhood emailed us an invitation to a barbecue for a club she was starting for "empty nesters." I get it. When our older son, Jonathan, left for college, it felt like a rift in the family fabric. Mickey, then 14, summed it up when he asked, "My brother doesn't live here anymore? Are we divorced?"
New indication for VIMPAT (lacosamide): UCB's anti-epileptic drug approved by FDA as monotherapy in the treatment of patients with partial-onset seizures
Brussels (Belgium), 1st September, 2014 – 0700 (CEST) – regulated information – UCB announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VIMPAT® (lacosamide) C-V as monotherapy in the treatment of partial-onset seizures in patients with epilepsy aged 17 years and older. This is a new indication for VIMPAT® which is already approved in the U.S. as adjunctive treatment for partial-onset seizures in patients in this age group. This new indication means that adults with partial-onset seizures can be initiated on VIMPAT® monotherapy, and patients already on an anti-epileptic drug can be converted to VIMPAT® monotherapy.
UCB also announced today that the FDA has approved a new single loading dose administration option for all formulations of VIMPAT®, when used as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in patients with epilepsy aged 17 years and older.
Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol as a Potential Treatment for Dravet Syndrome, a Rare Form of Epilepsy
PHOENIX, AZ--(Marketwired - Jul 2, 2014) - Insys Therapeutics, Inc. (NASDAQ: INSY), a specialty pharmaceutical company that is developing and commercializing innovative drugs and novel drug delivery systems, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its pharmaceutical cannabidiol (CBD) for the treatment of Dravet syndrome, a rare pediatric-onset epilepsy.
"There is presently no cure for this catastrophic form of epilepsy, and the significant, unmet need is recognized by the orphan drug designation we received today for our pharmaceutical CBD," said Michael L. Babich, President and Chief Executive Officer. "Our pharmaceutical CBD is an alternative to plant derived cannabinoids, one which we believe will provide significant medical benefits and better address the unmet needs of patients across multiple indications including Dravet syndrome. We expect to file an Investigational New Drug Application (IND) for CBD in the second half of 2014."
Insys has more than seven years of research and development experience in the pharmaceutical cannabinoid space. The company manufactures pharmaceutical dronabinol (THC) and pharmaceutical CBD, both of which are cannabinoids, at its FDA-inspected and Drug Enforcement Administration (DEA) approved facility in Round Rock, Texas. Insys believes it is the only U.S.-based company with the capacity to produce pharmaceutical cannabinoids in scalable quantities.
Statement Regarding Department Of Defense Epilepsy Funding Announcement
“CURE applauds the announcement today from the U.S. Department of Defense – allocating $7.5 million dedicated to epilepsy research – and thanks Senator Dick Durbin (D-IL) for his leadership on this issue. The incidence of epilepsy increased by an alarming 52 percent from 2006 to 2010, with approximately 8 percent of those afflicted having been diagnosed with traumatic brain injury (TBI). Twenty-four percent of military related epilepsy is associated with prior TBI.
An expert panel of leading researchers and clinicians will discuss the latest research on the diagnostic and therapeutic management of PCDH19 Female Epilepsy. This course is appropriate for, and designed to foster dialogue among Pediatric Neurologists, Pediatric Epileptologists and Pediatric Neurology RNs and NPs. In addition to providers who provide direct care for patients in routine clinical visits and in emergent situations, researchers, genetic counselors and families affected by PCDH19 will also benefit from this course.
Some kinds of epilepsy are rooted in physical trauma — a brain injury at birth, perhaps. Others seem to show up like bolts from the blue, with no clear event to explain them. Yet one thing is clear: many cases of idiopathic epilepsy — epilepsy without an obvious physical cause — run in families, implicating heredity in their genesis. Indeed, studies1 suggest that genetic variations in ion channels on the surface of neurons — electrically excitable cells in the nervous system — might lie at the heart of many cases of idiopathic epilepsy, and presumably cause the firing of these cells to get out of control.
But there is still much that scientists do not know about the genetics of idiopathic epilepsy. Currently, a gene variant can only be associated with 10–40% of patients, according to Holger Lerche, who researches the genetics of neurological disorders at the Centre for Integrative Neuroscience in Tübingen, Germany. “But actually, almost all idiopathic epilepsy is likely to be genetic, so this figure should be closer to 80–100%,” he says. “The problem is that we haven't identified all disease-associated genes just yet — nor how they interact.”
Adding to the complexity of the puzzle are the facts that two-thirds of healthy individuals carry a gene variant associated with epilepsy, that many genes pinpointed by genetic analyses are also implicated in other disorders, and that epilepsy often co-occurs with other diseases — 30% of children with autism also have epilepsy, for example. This makes it hard to connect a given genetic variant in a patient to one specific disease. Epilepsy is a complex genetic disorder involving interplay between many genes, often in unexpected ways.
Throughout history, in almost every culture, epilepsy has been viewed as something to be feared, avoided and concealed. In what is thought to be the earliest written description of the condition, dating from around 1050 BC, the Babylonians referred to it as miqtu, or 'the falling disease', and attributed it to ghosts and demons. The ancient Greeks called it 'the sacred disease' and believed that it resulted from divine intervention. Epilepsy even makes appearances in the Bible, when Jesus heals a boy who suffers from seizures by casting out a 'demon'.
By 400 BC, Greek physician Hippocrates concluded that seizures are hereditary and originate in the brain, yet this view failed to become widely accepted for hundreds of years.
Former Board Member Randy Siegel continues to spread the word about CURE, advancing scientific research at Wesleyan University
Thanks to an endowment gift from Randy Siegel '83, this summer Elizabeth Paquette '15 will be working on cutting-edge epilepsy research in the lab of Professor Janice Naegele.
Siegel, a College of Letters alumnus, and his wife Lisa have a very personal reason for making their gift: their daughter Rebecca, 17, has struggled with intractable epilepsy since she was a baby. (Son Richie is a sophomore at New York University). Several years ago Randy and Lisa were introduced to a young advocacy group called CURE Epilepsy by another couple with a severely epileptic daughter—Susan and David Axelrod. David is the former political strategist and senior advisor to President Obama, while Susan founded CURE. The Siegels became active members of the organization, and Randy recently completed a long stint as a board member.
CURE Grantee Christophe Bernard, PhD Leads Breakthrough on Understanding of Seizure Mechanisms Across Species
On a quest to answer, “What is epilepsy?” Dr. Christophe Bernard examined seizure activity across species, from flies to humans. The findings were recently published in a new paper that Dr. Bernard says is the ‘work he's most proud of in his career.’ Read more in his piece in HuffPost Lifestyle – UK.
Learning about Investigator-Stakeholder Team Engagement in Neurological Clinical Trials
On Tuesday, July 22nd, NINDS grantees at the University of Michigan will host a free one-day patient advocacy conference exploring patient-informed clinical trial design. The LISTEN conference [Investigator-Stakeholder Team Engagement in Neurological Clinical Trials] is sponsored by the NINDS-supported Neurological Emergencies Treatment Trials Network (NETT). In the event that you are not familiar with the NETT, this multi-center project conducts large-scale clinical trials to determine rapid interventions for a range of neurological disorders including, but not limited to, stroke, traumatic brain injury, seizure and infectious disorders.
CURE Research Director H. Steve White, Ph.D., Awarded for Contributions to the Field of Epilepsy and Seizures
CURE Research Director H. Steve White, Ph.D., who also serves as a professor of pharmacology and toxicology and principal investigator of the National Institutes of Health (NIH)-sponsored Anticonvulsant Drug Development Program at the University of Utah College of Pharmacy, has been named the 2014 recipient of the Epilepsy Foundation’s Lifetime Accelerator Award, in recognition of his commitment and pioneering contributions to the field of epilepsy and seizures. Dr. White will be honored at the 4th Biennial Epilepsy Pipeline Conference 2014, being held June 5-7, 2014, at the Hyatt Regency San Francisco.
The Board of Directors of Citizens United for Research in Epilepsy (CURE) is pleased to announce the appointment of Robin Harding as its CEO, effective June 23, 2014. CURE Board Chair Gardiner Lapham noted Harding’s breadth of non-profit leadership experience and the way her visionary, strategic and management skills align with the organization’s mission to drive innovative research that will lead to a cure for epilepsy.
Ms. Harding, who has served as the organization’s interim Executive Director for the past six months brings more than 25 years of progressive, successful leadership experience in the non-profit and corporate sector to CURE. She worked with the national headquarters of the Juvenile Diabetes Research Foundation (JDRF) for eight years culminating in the role of EVP and COO where, among other major accomplishments, she led the development and launch of their $1 billion five year global philanthropic campaign. Prior to that she served as the executive director of the local Illinois based chapter. Additionally, Harding worked as a director of development for six years for the Alzheimer’s Association in Chicago.
Seventy Medical Research Fellows to Embark on a Year in the Lab
Seventy of the nation’s top medical and veterinary students have been selected to participate in the 26th class of the HHMI Medical Research Fellows Program, a $2.8 million annual initiative to increase the training of future physician-scientists. The students will put their medical studies on hold for one year to conduct intensive, mentored biomedical research at 32 fellowship institutions across the country.
This year, HHMI received 191 fellowship applications from students representing 68 institutions. Each applicant was required to submit a research plan to work in a specific lab with a mentor they had identified.
“Autoimmune Causes of Epilepsy”
Wednesday, May 7, 2014
The Epilepsy Center of Excellence and the Employee Education System are proud to announce a series of audio conferences providing continuing education to VA providers to improve the health, well-being, and clinical care of Veteran patients with epilepsy and other seizure disorders.
1:00 PM – 2:00 PM Eastern Time
10:00 AM – 11:00 AM Pacific Time
Courtagen to Provide Genetic Profiling of Children with Intractable Epilepsy to Support Clinical Developments with Cannabidiol
Using the latest next-generation sequencing technologies, Courtagen is collaborating with various academic centers and US physicians to profile the genomes of intractable epilepsy patients to stratify response to cannabidiol (CBD).
Courtagen Life Sciences, an innovative molecular information company, announces a new comprehensive epilepsy sequencing test designed to sequence 489 genes known to be involved in epilepsy, antiepileptic drug metabolism, and endocannabinoid regulation. This panel is to be the first deployed in the genetic analysis of over 100 children suffering from intractable epilepsy syndromes.
The FDA has granted orphan drug designation for GW Pharmaceuticals’ Epidiolex®, the product candidate that contains plant-derived cannabidiol (CBD) as its active ingredient for use in treating children with Dravet syndrome, as well as Lennox-Gastaut syndrome, two rare and severe forms of infantile-onset, genetic, drug-resistant epilepsy syndromes. Epidiolex is an oral liquid formulation of a highly purified extract of CBD, a non-psychoactive molecule from the cannabis plant. The FDA has approved expanded access to the Investigational New Drug (IND) to several independent physicians in the U.S. in order to allow treatment of approximately 125 pediatric epilepsy patients with Epidiolex.
WEBINAR: Epilepsy-Related Mortality: The Untold Toll on Public Health
Sign up now for this April 3 webinar. Space is limited.
Most people with epilepsy live a full and healthy life. However, people can die from epilepsy. Some people with epilepsy may lose their lives from accidents, drowning, suicide or the underlying cause of their condition, such as tumors or genetic syndromes. The leading cause of epilepsy-related death is believed to be SUDEP (Sudden Unexpected Death in Epilepsy).
During this webinar you will learn about the epidemiology of mortality in epilepsy, including the kinds or mortality data the CDC collects and how they collect it. We will present the most up-to-date statistics on epilepsy mortality in the U.S. and what this means for people living with epilepsy. You will also learn about some of the efforts to collect more accurate data, including the Sudden Death in Young Registry. We will conclude this presentation with highlights of what to expect from the Partners Against Mortality in Epilepsy (PAME) 2014 meeting and why we have expanded the content to include epilepsy mortality more broadly in addition to our focus on SUDEP.
ECoE Sponsors a Free Audio Conference March 19 - "Diagnosis and Management of Status Epilepticus"
ECoE Healthcare Providers FY14 Education Audio Conference
Sponsored by Epilepsy Centers of Excellence & Employee Education System
“Diagnosis and Management of Status Epilepticus” Wednesday, March 19, 2014
1:00 PM – 2:00 PM Eastern Time
10:00 AM – 11:00 AM Pacific Time
The Epilepsy Center of Excellence and the Employee Education System are proud to announce a series of audio conferences providing continuing education to VA providers to improve the health, well-being, and clinical care of Veteran patients with epilepsy and other seizure disorders.
Epilepsy Research Grants Awarded By Cure After Receiving Record-High Number Of Applications
February 13, 2014, Chicago, IL – After receiving a record-high 200 plus applications in 2013, Citizens United for Research in Epilepsy (CURE) is proud to announce its six research grant recipients for the Taking Flight and Innovator awards.
The surge in applications is credited to CURE’s ongoing efforts to drive the epilepsy research agenda, funding innovative science not currently being explored by other institutions.
“This was the first year we were unable to fund all of the grants we would have liked to,” said Dr. Steve White, research director for CURE. “The applications received in 2013 were extremely competitive and filled with state-of-the-art science that promises to advance our understanding of the forms of epilepsy.”
Each year, the most promising grants are selected and funded on the basis of the scientific investigations proposed and the potential that the investigations will lead to a greater understanding of the forms of epilepsy and new therapies that could ultimately lead to a cure.
Savannah Salazar went to bed one night in 1995 as a typical toddler. At two and a half years old, she could count to three and knew most of her colors, although she still mixed up black and brown. As far as her parents could see, she was developing pretty much the same way her four-year-old brother had.
And then, in the middle of that night, everything changed. Her parents, Ruben Salazar and Tracy Dixon-Salazar (who is now Dr. Dixon-Salazar), awoke to a sound every parent dreads: their daughter was choking. “She was gagging, hacking, and making frothing noises,” Dr. Dixon-Salazar recalls. “I thought my child was dying. By the time the paramedics came, Savannah was okay. But I'll never forget what one of them said next: ‘Her airway is clear, but what you've just described sounds like a seizure.’”
Savannah didn't go to the hospital that night. Her exhausted parents tried to go back to bed. But when Savannah had another seizure a couple of weeks later—and a total of four within a period of two months—the family embarked on a seemingly endless roller coaster of scans, tests, and doctor visits: blood tests, magnetic resonance imaging (MRI), computed tomography (CT) scans, electroencephalography (EEG)—but they all came back normal.
Marijuana-Derived Epilepsy Drug in Clinical Trial for Children with Uncontrolled Seizures
A new international multi-center study led by researchers from UCSF Benioff Children’s Hospital is the first to evaluate whether purified cannabinoid is effective in treating severe forms of childhood epilepsy that do not respond to standard antiepileptic drugs.
“Better treatment for children with uncontrolled seizures is desperately needed,” said Maria Roberta Cilio, MD, PhD, principal investigator for the multi-center study and director of research at the UCSF Pediatric Epilepsy Center. “It’s important to get seizure control at any age, but in children, uncontrolled seizures may impact brain and neurocognitive development, which can have an extraordinary effect on quality of life and contribute to progressive cognitive impairment.”
The drug, called Epidiolex, is a purified cannabinoid that comes in a liquid form containing no tetrahydrocannabinol (THC), the psychotropic component in cannabis. Produced by the biopharmaceutical company GW Pharmaceuticals, Epidiolex is considered a schedule 1 substance by the U.S. Food and Drug Administration (FDA) and is closely monitored and restricted by both the FDA and U.S. Drug Enforcement Agency.
The trial will enroll a total of 150 patients across six centers. The study began earlier this month at UCSF Benioff Children’s Hospital and is also underway at NYU Langone Medical Center. Pending FDA approval, it will launch at four additional institutions this year.
ECoE Sponsors a Free Audio Conference February 13 Discussing Quality of Epilepsy Care
ECoE Patient and Caregiver FY14 Education Audio Conference
Sponsored by the Epilepsy Centers of Excellence & Employee Education System
The Epilepsy Center of Excellence and the Employee Education System are proud to announce a series of audio conferences providing continuing education to VA providers to improve the health, well-being, and clinical care of Veteran patients with epilepsy and other seizure disorders.
Science Translational Medicine Publishes Paper by CURE Grantee Jeff Noebels, MD, PhD
Infantile spasms syndrome (ISS) is a devastating form of childhood epilepsy characterized by involuntary,massive motor spasms during early infancy that herald a lifelong disorder of severe seizures and intellectual disability. Mutations in a growing list of genes critical for the establishment of proper neural networks during development have been associated with its many inherited forms. ISS responds poorly to typical anticonvulsant drugs, and despite the lack of a known mechanism, the synthetic glucocorticoid prednisone and adrenocorticotropic hormone (ACTH) remain the primary initial treatments. Although short-term spasm reduction can be achieved, high relapse rates, cognitive impairment, and long-lasting side effects highlight the need for more effective therapy.
Three million Americans currently live with epilepsy. Of these, one-third of patients do not respond to any of the currently available treatments. Most people cannot imagine the horror of watching a loved one have even one seizure; yet 1 in 26 Americans will develop epilepsy in their lifetime.
As the leading private funder of epilepsy research, CURE recognizes the emerging need for scientifically rigorous investigations into the mechanisms and efficacy of cannabidiol (CBD) for the treatment of epilepsy. It is important to clarify that many believe it is CBD (the non-psychoactive component of "medical marijuana”) that helps patients.
VIDEO: How Did a Neuroscientist Ameliorate Seizures in her Daughter's Lennox-Gastaut Syndrome?
In this video segment, Neurology Today’s Editor-in-Chief Steven P. Ringel, MD, talks with Tracy Dixon-Salazar, PhD, associate research director at Citizens United for Research in Epilepsy, about her journey from being a stay-at-home mom to going back to school — earning an associate’s, bachelor’s, master’s, and finally a PhD in neurobiology at University of California, San Diego — that led her to sequencing and identifying mutations in her daughter Savannah and finding an off-label treatment, verapamil (a calcium channel blocker) that helped reduce her daughter’s seizures by 95 percent.
NIH Announces Six Funding Opportunities for the BRAIN Initiative in Fiscal 2014
The National Institutes of Health is releasing funding opportunities to build a new arsenal of tools and technologies for unlocking the mysteries of the brain. The NIH action is in support of President Obama’s Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative.
The six opportunities announced today were developed in response to high priority areas identified by the NIH Advisory Committee to the Director’s BRAIN Working Group in September 2013. Awards are expected to be announced in September 2014 and will constitute NIH’s initial investment of $40 million in the initiative.
“The human brain is one of the most complicated structures in the known universe,” said NIH Director Francis S. Collins, M.D., Ph.D. “We have an unprecedented opportunity to develop new technologies that will allow us to map the circuits of the brain, measure activity within those circuits, and understand how their interactions maintain health and modulate human behavior.”
The President’s BRAIN Initiative is a large-scale inter-agency federal effort that the President described as “giving scientists the tools they need to get a dynamic picture of the brain in action and better understand how we think, how we learn, and how we remember.” Three federal agencies — NIH, National Science Foundation, and Defense Advanced Research Projects Agency, or DARPA — expect to contribute a total of $110 million in the 2014 fiscal year. NIH’s $40 million contribution in fiscal 2014 is in addition to the roughly $5.5 billion slated in the NIH fiscal 2014 budget for neuroscience research. Private organizations have also signed on to bolster this bold, interdisciplinary effort.
WEBINAR: Understanding SUDEP Research and the Role You Can Play
Ending sudden unexplained death in epilepsy (SUDEP) is a shared responsibility. And you can help! Any successful effort will require doctors, people with epilepsy, nurses, researchers, coroners and those bereaved by the loss of someone to SUDEP to work together. It will require collaboration across many different organizations over many years. During this webinar we will begin with a look at what research is telling us about the possible causes as well as future prevention methods and cures for SUDEP.
Acorda Presents New Data on Diazepam Nasal Spray at 67th Annual Meeting of American Epilepsy Society
ARDSLEY, N.Y.—Dec 9, 2013-- Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that new data from a pharmacokinetics study on Diazepam Nasal Spray found comparable pharmacokinetics (PK) whether the drug was administered during or immediately after a seizure. These data were presented at the 67th Annual Meeting of the American Epilepsy Society, in Washington, D.C. Diazepam Nasal Spray is being developed for the treatment of people with epilepsy who experience cluster seizures, also known as acute repetitive seizures.
“In this study, some patients received a dose of Diazepam Nasal Spray while having a seizure, while others received the dose after their seizure activity had ceased,” said Adrian Rabinowicz, M.D., FAAN, Acorda's Senior Vice President of Clinical Development and Medical Affairs. “The results suggest that delivery of Diazepam Nasal Spray was unaffected by the timing of dosage relative to seizure activity. It is critical for a person with epilepsy who experiences cluster seizures that treatment be administered as soon as possible after a cluster is recognized, in order to prevent additional seizure activity.”
This multicenter, open-label study was conducted in adults admitted to an epilepsy monitoring unit for evaluation and management of epilepsy. Of the 30 patients who completed the study, 10 were dosed during a seizure, while the other 20 patients were dosed after their seizure activity had ceased. Plasma concentrations of diazepam were measured for a period of up to 12 hours following the dose.
Univ. of Colorado Professor Amy R. Brooks-Kayal, M.D. Named First Vice President of American Epilepsy Society
Washington, D.C., December 9, 2013 – Amy R. Brooks-Kayal, M.D., Professor with Tenure of Pediatrics, Neurology and Pharmaceutical Sciences at the University of Colorado School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, and Ponzio Family Chair and Chief of Pediatric Neurology at Children’s Hospital Colorado, over the weekend was elected first vice-president of the American Epilepsy Society (AES), during the Society’s 67th annual meeting and scientific conference at the Washington (DC) Convention Center.
AES is the 3,000-member society of physicians, scientists and allied healthcare professionals dedicated to the prevention, treatment, and cure of epilepsy. Dr. Brooks-Kayal’s new AES board position puts her in line to head the organization at the end of the current president’s term in office.
Dr. Brooks-Kayal is a practicing epileptologist at Children’s Hospital Colorado. She also leads an NIH-funded research program focused on the molecular mechanisms underlying epilepsy and the development of new targeted- therapies for epilepsy prevention and disease modification.
Seizure Triggers: How to Deal with Them and Prevent Seizures
ECoE Patient and Caregiver FY14 Education Audio Conference
Sponsored by Epilepsy Centers of Excellence & Employee Education System
Thursday, December 5, 2013
1:00 PM EASTERN TIME
10:00 AM PACIFIC TIME
Maria Lopez, MD Epilepsy Center of Excellence, Miami VA Medical Center
The Epilepsy Center of Excellence and the Employee Education System are proud to announce a series of audio conferences providing education and training to patients and caregivers to improve the health and well-being of Veteran patients with epilepsy and other seizure disorders.
Marijuana has been used medically, recreationally and spiritually for about 5,000 years. Known botanically as cannabis, it has been called a “crude drug”: marijuana contains more than 400 chemicals from 18 chemical families. More than 2,000 compounds are released when it is smoked, and as with tobacco, there are dangers in smoking it.
Medical marijuana clinics operate in 20 states and the District of Columbia, and its recreational use is now legal in Colorado and Washington. A Gallup poll conducted last month found that 58 percent of Americans support the legalization of marijuana.
Yet researchers have been able to do relatively little to test its most promising ingredients for biological activity, safety and side effects. The main reason is marijuana’s classification by Congress in 1970 as an illegal Schedule I drug, defined as having a potential for abuse and addiction and no medical value.
American scientists seeking clarification of marijuana’s medical usefulness have long been stymied by this draconian classification, usually reserved for street drugs like heroin with a high potential for abuse.
Some years ago, across a crowded room, I met and quickly became friends with the most elegant of women, Susan Axelrod. That we hadn’t met earlier in our lives is a puzzle. Her sister-in-law was a woman I knew well. And our husbands had interacted many times over news and politics, sharing dinners and war stories during conventions, at least one of which I attended. We lived in parallel worlds, with Susan in Chicago and me in Boston, before we finally met in Washington at a tribute to Sen. Ted Kennedy shortly before his death.
The question is: What did I do without Susan before I met her? In each of our lives there is the girlfriend we share our secrets with, the colleagues we consult with, the other mothers we compare notes with. But when you have a child who has a chronic medical issue — as both Susan Axelrod and I have — the road narrows. The issues are complex, the medical problems can feel unending and the emotions are often raw. Your child grows into an adult and your hopes are the same as you would have for any one of your kids. You want them to have happiness, health and a productive life. But, for you and for them, it’s far more complicated, sometimes overwhelming and at times simply out of reach.
Brain Connectivity Can Predict Epilepsy Surgery Outcomes
A discovery from Case Western Reserve and Cleveland Clinic researchers could provide epilepsy patients invaluable advance guidance about their chances to improve symptoms through surgery. Assistant Professor of Neurosciences Roberto Fernández Galán, PhD, and his collaborators have identified a new, far more accurate way to determine precisely what portions of the brain suffer from the disease. This information can give patients and physicians better information regarding whether temporal lobe surgery will provide the results they seek.
ECoE Sponsors a Free Audio Conference November 6 Discussing Treatment of Elderly with Epilepsy
VA ECoE Healthcare Providers FY14 Education Audio Conference Sponsored by the Epilepsy Centers of Excellence & Employee Education System
The Epilepsy Center of Excellence and the Employee Education System are proud to announce a series of audio conferences providing continuing education to VA providers to improve the health, well-being, and clinical care of Veteran patients with epilepsy and other seizure disorders.
NIH and CDC Launch Registry for Sudden Death in the Young
A registry of deaths in young people from conditions such as heart disease and epilepsy is being created to help researchers define the scope of the problem and set future research priorities. The National Institutes of Health and the Centers for Disease Control and Prevention are collaborating to create the Sudden Death in the Young Registry.
"The sudden death of a child is tragic and the impact on families and society is incalculable," said Jonathan Kaltman, M.D., chief of the Heart Development and Structural Diseases Branch within the Division of Cardiovascular Sciences at the NIH's National Heart, Lung, and Blood Institute (NHLBI). "This registry will collect comprehensive, population-based information on sudden unexpected death in youths up to age 24 in the United States. It is a critical first step toward figuring out how to best prevent these tragedies."
Cases of sudden cardiac death or sudden unexpected death in epilepsy (SUDEP) are not routinely or systematically reported, and no commonly agreed upon standards or definitions for reporting currently exist. Complete information has not been collected on the incidences, causes, and risk factors for sudden death in the young. The lack of evidence fuels disagreements about the best prevention approach. Sudden cardiac death, also called sudden cardiac arrest, happens when the heart suddenly and unexpectedly stops beating and blood stops flowing to the brain and other vital organs.
CURE Awards $2 Million to Grantees for Research in Epilepsy
October 21, 2013, Chicago, IL - Citizens United for Research in Epilepsy (CURE), the leading nongovernmental funder of epilepsy research, is proud to announce the most recent recipients of research grants awarded this year. Over $2 million was awarded in this cycle.
“These investigators have demonstrated they understand the urgency in finding cures for the epilepsies, and we are confident in their abilities to accelerate breakthroughs,” stated Susan Axelrod, Founding Chair of CURE.
Researchers identify key proteins that are involved in the worsening of epilepsy and associated behavioral issues
CURE-funded research has shown that normal function of SNARE proteins (proteins important for releasing chemicals to signal neurons) found on star-shaped glia cells in the brain, called astrocytes, is crucial for seizures to progress in frequency and severity. Decreasing SNARE function limited seizures and epilepsy progression. This was also true for behavioral deficits and inflammation where blocking SNARE protein action was show to decrease both. Studies like these may help us to understand why certain types of epilepsy can worsen over time and cause a myriad of behavioral and cognitive effects that are detrimental to patients.
Two-hundred fifty patients were referred by their physician to have their whole exome sequenced (the exome is the part of the genome that codes for proteins), of which most were children with neurological disorders such as epilepsy. Researchers then took these patients’ exome data and analyzed it. They were able to identify the cause of the disorder in 25% of the patients. This is significant because it states that 25 out of 100 patients who don’t know the cause of their disorder could have the genetic cause identified using this method.
A congregation of zebrafish larva - each about the size of an eyelash and translucent with bulging black eyes - darted violently under the lens of a microscope.
The tiny fish are key players in UCSF neuroscientist Scott Baraban's quest to understand first how seizures in humans develop and then how to prevent them. Working with fish has accelerated his research, allowing him to uncover potential epilepsy treatments with incredible speed and at a fraction of the cost compared with mice.
Those advantages and others have caused labs around the world to increasingly turn to zebrafish for research, using them to study everything from epilepsy to environmental toxins.
"There has been something like a Cambrian explosion in zebrafish research in the past 10 years," said Zoltan Varga, director of the Zebrafish International Resource Center at the University of Oregon.
In 2002, the center recorded about 330 scientific labs working with the fish. By 2012, that number had grown to more than 800.
Annals of Neurology Publishes 2012 CURE Grantee’s Paper
Published in the September issue of Annals of Neurology was a paper by Vanderbilt University investigator and CURE Grantee Jingqiong (Katty) Kang. Dr. Kang’s work focuses on Dravet Syndrome, a severe form of infantile epilepsy. Genetic changes in the gene that codes for a major inhibitory receptor in the brain (GABRG2) can cause Dravet Syndrome, but it can also cause less severe forms of epilepsy. Dr. Kang’s work shows that different types of genetic changes in this gene can lead to the differences in epilepsy seen in patients. For example, patients who have a truncating mutation early in the sequence of this gene, have more severe seizures than patients who have a truncating mutation later in the gene sequence. This work explains how patients with defects in the same gene might have very different types of epilepsy and lays the foundation for future work aimed at stopping seizures in these patients.
FOA: Centers Without Walls for Collaborative Research in the Epilepsies: Sudden Unexpected Death in Epilepsy (SUDEP)
NIH/NINDS issued a request for applications to obtain funding to accelerate the rate of progress in understanding the underlying causes and contributing factors to SUDEP and work toward interventions that prevent SUDEP.
This purpose of this Funding Opportunity Announcement (FOA) is to support a multicenter, multidisciplinary research team to accelerate the rate of progress in identifying the underlying mechanisms that cause SUDEP, identify risk factors of SUDEP for individuals with epilepsy, and/or develop prevention strategies to reduce SUDEP rates. It is expected that advances in understanding the underlying mechanisms of SUDEP will enable more rapid translation of targeted clinical therapies and prevention strategies.
Potential Epilepsy Drug Discovered Using Zebrafish
An antihistamine discovered in the 1950s to treat itching may also prevent seizures in an intractable form of childhood epilepsy, according to researchers at UC San Francisco who tested it in zebrafish bred to mimic the disease.
The researchers said their unexpected discovery offers a glimmer of hope for families of children with Dravet Syndrome, a rare genetic disorder that manifests in early childhood with disabling, lifelong consequences. These include dozens, if not hundreds, of daily seizures, as well as profound cognitive and social deficits.
“It is very unfortunate for these children and families, as they often live from seizure to seizure,” said Scott C. Baraban, PhD, lead author of the article, UCSF William K. Bowes Jr. Endowed Chair in Neuroscience Research and professor of Neurological Surgery.
Small, translucent and easy to breed, zebrafish are increasingly being used in place of rodents to screen drugs for rare genetic disorders. But no one had used them for epilepsy drug screening until Baraban’s team found zebrafish with a genetic mutation identical to the one that causes Dravet Syndrome.
New Epilepsy Research Could Lead To Targeted Treatments
New genetic research could provide life-changing treatments for the approximately 50 million people with epilepsy worldwide.
A study in the journal Nature has identified two genes and 25 mutations associated with the most serious forms of epilepsy.
By identifying these genes, doctors can develop targeted treatments.
Dr. David Goldstein, director of the Duke Center for Human Genome Variation, and Tracy Dixon-Salazar, a neurobiologist who is associate research director for Citizens United for Research in Epilepsy, join Here & Now to discuss the new research.
Dixon-Salazar started studying neurobiology when her daughter Savannah was diagnosed with a childhood epilepsy.
A manuscript from the workshop “Priorities in Pediatric Epilepsy Research: Improving Children’s Futures Today” will be published in the August 21 issue of Neurology®, the medical journal of the American Academy of Neurology. Epilepsy affects 1/26 people over the course of the lifespan; 10 percent of that risk is concentrated in the first two to three years of life.
Citizens United for Research on Epilepsy (CURE) funded the workshop which focused on infants and toddlers with epilepsy, and involved stakeholders including pediatric epilepsy care providers, educators, clinical researchers, and, most importantly, parents of children with epilepsy. Four themes came out of the workshop: patient outcomes, diagnosis, role of parents and resources outside the medical system; all with an emphasis on early onset epilepsy for children three and under.
“As the mother of a daughter who developed epilepsy during this vital time in her development, I know how critically important control of early life seizures is,” said Susan Axelrod, CURE’s Founding Chair. “I was personally proud of CURE's support and involvement with this workshop because we must pull together all available resources to prevent the lifelong and serious effects epilepsy so often has on children. Workshops like this give these children the best shot at a normal, healthy life."
Caffeine consumption during pregnancy and its effects on the brain during development
Caffeine is the most consumed psychoactive substance in the world, including during pregnancy. Christophe Bernard, Inserm research director, and his team within the "1106 Institut de Neurosciences des Systèmes" unit (Inserm/Aix-Marseille University), have recently described certain harmful effects after caffeine consumption by female mice during pregnancy on the brains of their offspring. This work, despite performed in rodents, suggests that careful studies should be performed to assess the consequences of caffeine consumption by women during pregnancy.
These results are being published in the Science Translational Medicine review of 7th of August 2013.
Many substances have a direct effect on brain function, by modifying the activity of neurons. This applies to antidepressants, anti-anxiety drugs, nicotine, alcohol and recreational drugs such as cannabis, heroin, cocaine, etc. These substances, known as psychoactive substances, bind to proteins present in brain cells and modify their activity. When consumed during pregnancy some of these psychoactive substances can affect the construction of the fetal brain, as the proteins to which they bind play key roles in brain development. The consumption of some of these substances is thus strongly discouraged during pregnancy.
Newly Identified Genetic Factors Drive Severe Childhood Epilepsies
DURHAM, N.C. -- Researchers have identified two new genes and implicated 25 distinct mutations in serious forms of epilepsy, suggesting a new direction for developing tailored treatments of the neurological disorders.
The findings by an international research collaboration, which includes investigators from Duke Medicine, appear Aug. 11 in the journal Nature.
Epileptic encephalopathies are a devastating group of severe brain disorders characterized by the onset of seizures at an early age. The seizures are often accompanied by cognitive and behavioral issues, which can hinder the quality of life of affected children and their families.
The cause of epileptic encephalopathies is largely unknown; while genes are believed to play an important role, specific genes have only been identified in a small number of cases.
“One important aspect of the study is that we identified an unusually large number of distinct disease-causing mutations -- 25 in total, all of which were de novo mutations. These mutations will be an invaluable resource to scientists working to elucidate the underlying causes of the epilepsies,” said study author David Goldstein, PhD, director of the Duke Center for Human Genome Variation.
A de novo mutation is a new alteration in a gene that appears for the first time in a family, and results from a genetic mutation in a parent’s germ cell (egg or sperm).
Learning more about the disorders’ origin will guide development of effective therapies, which is the goal of Epi4K, an international research consortium funded by the National Institute of Neurological Diseases and Stroke (NINDS).
Silky brain implants may help stop spread of epilepsy
CURE is proud to have funded pilot work with Dr. Boison showing that adenosine is involved in epilepsy and it’s a rational target for therapy. In this study, he shows that putting adenosine directly in the brain, it lessened the epilepsy over time.
Silk has walked straight off the runway and into the lab. According to a new study published in the Journal of Clinical Investigation, silk implants placed in the brain of laboratory animals and designed to release a specific chemical, adenosine, may help stop the progression of epilepsy. The research was supported by the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute of Biomedical Imaging and Bioengineering (NIBIB), which are part of the National Institutes of Health.
The epilepsies are a group of neurological disorders associated with recurring seizures that tend to become more frequent and severe over time. Adenosine decreases neuronal excitability and helps stop seizures. Earlier studies have suggested abnormally low levels of adenosine may be linked to epilepsy.
Rebecca L. Williams-Karnesky, Ph.D. and her colleagues from Legacy Research Institute, Portland, Ore., Oregon Health and Sciences University (OHSU), Portland, and Tufts University, Boston, looked at long-term effects of an adenosine-releasing silk-implant therapy in rats and examined the role of adenosine in causing epigenetic changes that may be associated with the development of epilepsy.
"Epilepsy in a dish": Stem cell research reveals clues to disease's origins and may aid search for better drugs
ANN ARBOR, Mich. — A new stem cell-based approach to studying epilepsy has yielded a surprising discovery about what causes one form of the disease, and may help in the search for better medicines to treat all kinds of seizure disorders.
The findings, reported by a team of scientists from the University of Michigan Medical School and colleagues, use a technique that could be called “epilepsy in a dish”.
By turning skin cells of epilepsy patients into stem cells, and then turning those stem cells into neurons, or brain nerve cells, the team created a miniature testing ground for epilepsy. They could even measure the signals that the cells were sending to one another, through tiny portals called sodium channels.
In neurons derived from the cells of children who have a severe, rare genetic form of epilepsy called Dravet syndrome, the researchers report abnormally high levels of sodium current activity. They saw spontaneous bursts of communication and “hyperexcitability” that could potentially set off seizures. Neurons made from the skin cells of people without epilepsy showed none of this abnormal activity.
Anti-rejection drug reduces seizures in patients with genetic disorder, say doctors at Texas Children's Hospital, Baylor College of Medicine and Cincinnati Children's Hospital
Everolimus, a drug used to treat cancers and prevent rejection of transplanted organs, reduced the occurrence of seizures in patients with a genetic disorder called tuberous sclerosis complex in a small prospective study conducted by experts at Texas Children's Hospital, Baylor College of Medicine and Cincinnati Children's Hospital Medical Center and reported online in the journal Annals of Neurology (http://onlinelibrary.wiley.com/doi/10.1002/ana.23960/abstract).
Tuberous sclerosis complex results from faulty signaling in a key molecular pathway, causing abnormal cell growth that affects the skin, brain, lungs and heart, said Dr. Angus Wilfong, director of the comprehensive epilepsy program at Texas Children's Hospital and associate professor of pediatrics and neurology at Baylor College of Medicine. The seizures suffered by patients with the disorder occur because of the abnormal growths in the brain, said Wilfong, an author of the report.
Everolimus suppresses the activity of the mTOR pathway, which is overactive in this disorder, said Wilfong.
Patients with early onset and transient symptoms in early Alzheimer's disease -- or its harbinger, amnestic mild cognitive impairment (MCI) -- may also be experiencing seizures, which often aren't convulsive in this setting, researchers suggested.
Epilepsy or subclinical epileptic brain activity was associated with 5.5 to 6.8 years' earlier presentation with cognitive decline symptoms, Keith Vossel, MD, MSc, of the Gladstone Institute of Neurological Disease in San Francisco, and colleagues reported.
Fully 55% of epilepsy in Alzheimer's and amnestic MCI was nonconvulsive, instead being marked by transient cognitive symptoms such as aphasia, amnestic spells, sensory phenomena, or deja vu.
Those features should raise clinical suspicion for seizures, the group suggested online in JAMA Neurology.
"Careful identification and treatment of epilepsy in such patients may improve their clinical course," they wrote, adding that the "findings add to the mounting evidence that Alzheimer's disease-related neural network hypersynchrony is an early and potentially treatable component of the disease."
In Montreal, Call for Openness on 'Sudden Unexpected Death in Epilepsy' - Epilepsy Can be a Deadly Disease
Experts and epilepsy organisations call for openness on Sudden Unexpected Death in Epilepsy (SUDEP) as global SUDEP campaign reaches new high at the 30th International Epilepsy Congress in Montreal 23rd to 27th June.
Epilepsy, like heart disease and stroke, ranks in the top ten causes of premature deaths and these deaths are potentially avoidable. Lack of public awareness of epilepsy mortality has meant research and treatment has lagged behind. Up to 1% of Canadians are affected by epilepsy, and this condition is more common in children. Many young and healthy people have lost their lives. Initiatives are underway in research, awareness and support for families affected, but funds are urgently needed.
Each year, about one in every thousand people with epilepsy will die suddenly with no obvious cause. This is known as Sudden Unexpected Death in Epilepsy (SUDEP) and the risk rises to 1:150 for people with seizures that are poorly controlled with medication. SUDEP, when a person with epilepsy dies suddenly and no other cause of death is found, is now recognised as a major cause of mortality associated with epilepsy and one with devastating consequences.
CURE Grantee Dr. James McNamara: 2-week treatment found to prevent epilepsy in mice gives hope for drug development
Temporal lobe epilepsy, the most common form of epilepsy, is characterized by recurrent seizures throughout life and often behavioral abnormalities, with devastating impacts on patients and their families. Unfortunately, the condition is often not responsive to anticonvulsants. Now scientists report online June 20 in the Cell Press journal Neuron that targeting a particular signaling pathway in mice can prevent the development of temporal lobe epilepsy with just two weeks of treatment, offering hope that researchers will be able to develop effective drugs to mitigate recurrent seizures and the development of epilepsy. Many patients with temporal lobe epilepsy experience an initial episode of prolonged seizures, known as status epilepticus, which is often followed by a period of seizure-free recovery before individuals develop recurring seizures. Research in animals suggests that the prolonged seizures in status epilepticus cause or contribute to the development of epilepsy.
"An important goal of this field has been to identify the molecular mechanism by which status epilepticus transforms a brain from normal to epileptic," says Dr. James McNamara, of the Duke University Medical Center in Durham. "Understanding that mechanism in molecular terms would provide a target with which one could intervene pharmacologically, perhaps to prevent an individual from becoming epileptic."
At CURE's 15th Annual Chicago Benefit, Guest of Honor Hillary Rodham Clinton Credits Breakthroughs in Research as Progress toward Cure for Epilepsy
Citizens United for Research in Epilepsy (CURE) held their 15th Annual Chicago Benefit at the Navy Pier Grand Ballroom on Thursday, June 13, 2013. More than 1,000 guests joined CURE founder and Chair Susan Axelrod and David Axelrod to support cutting-edge epilepsy research and raised nearly $1.5 million. The funds will go toward finding a cure for epilepsy.
Former Secretary of State Hillary Rodham Clinton gave an impassioned speech detailing her personal involvement with the cause, and recalling the first CURE dinner in 1999, where she was the keynote speaker, and imploring guests to raise their voices on behalf of the cause.
“All along the way CURE was at the forefront,” remarked Mrs. Clinton to a sold-out crowd. “We are now at a point, because of the mapping of the human genome - and because of breakthroughs in brain research - that for the first time we can really begin to unravel the mystery of epilepsy.”
With Epilepsy Treatment, The Goal Is To Keep Kids Seizure-Free
Barton Holmes was 16 months old when he had his first seizure. "He was convulsing and his eyes were rolling in the back of his head," his mother, Catherine McEaddy Holmes, says. "His lips were blue. I thought he was dying."
The seizure ended in less than a minute. And by the time an ambulance arrived, Barton was back to his old self. Even so, doctors at Children's National Medical Center in Washington, D.C., where the family lives, kept him overnight while they tried, without success, to figure out what had caused the seizure.
When Barton had a second seizure 10 days later, doctors didn't hesitate. "They were very aggressive and wanted us to start medication immediately," Holmes says. So Barton, who is 2 now, began taking an antiepileptic drug called Keppra.
BALTIMORE -- Cardiopulmonary abnormalities were associated with predictable patient and seizure characteristics in in children with epilepsy, researchers reported here.
Seizure-related apnea was associated with younger age, symptomatic-generalized seizure (versus primary-generalized seizure), seizure duration, anti-epileptic drug use, and seizure-related bradycardia, according to Kanwaljit Singh, MD, of Boston Children's Hospital, and colleagues.
Seizure-related tachypnea was associated with age, right-sided seizure, and was inversely related to anti-epileptic drug use, Singh said in a poster presentation during the Associated Professional Sleep Societies meeting.
As announced earlier this year, CURE has partnered with the Howard Hughes Medical Institute’s (HHMI) Medical Research Fellows Program to provide support for up to three medical students to conduct mentored research on epilepsy.
CURE is pleased to announce that two students have been chosen as HHMI-CURE Medical Fellows.
img align="right" class="picRightTopNoBorder" src="http://www.cureepilepsy.org/images/shared/ECoE.jpg" />Description: The Epilepsy Center of Excellence and the Employee Education System are proud to announce a series of audio conferences providing education and training to VA patients and caregivers to improve the health and well-being of Veteran patients with epilepsy and other seizure disorders.
Identify the impact of Epilepsy on memory
Describe types of memory loss
Discuss epileptic phases in which memory loss occurs
Explain the effects of Epilepsy treatment on memory
Identify interventions which may enhance recall and memory preservation
Cell Transplant Holds Significant Potential for Patients with Epilepsy
Chicago, May 6, 2013 - In a new paper published in Nature Neuroscience, a group of investigators at University of California, San Francisco suggest that an interneuron-based cell transplant holds therapeutic potential in animals with epilepsy, and offers real hope for its potential in humans.
Scott Baraban, PhD, Robert Hunt, PhD and colleagues report that injecting progenitors, or stem cells, of inhibitory neurons into the hippocampus of adult epileptic mice (the region of the brain necessary for learning and memory) reduced the frequency of seizures and restored behavioral deficits in spatial learning.
This study provides powerful preclinical evidence that stem cell transplantation should continue to be studied as a potential novel therapy for people with epilepsy.
In 2004, CURE granted Dr. Baraban a 1-year, $50,000 award to study whether transplanted stem cells can survive and functionally integrate into the brain of adult mice; in 2007, he was awarded another 1-year grant for $75,000. The goal of this grant was to use the transplantation technique he had validated and see if he could correct abnormal brain activity in a mutant mouse.
CURE Forms First Dream Team to Fight Childhood Epilepsy Syndrome
Since announcing the launch of its new Infantile Spasms Research Initiative last month, Citizens United for Research in Epilepsy (CURE) has awarded eight teams of investigators with $1.3 million in grants to proceed with cutting-edge research to find a cure for infantile spasms, a rare childhood epilepsy syndrome. Infantile Spasms (IS) can have profoundly negative long-term developmental and cognitive consequences. Currently available treatments are often ineffective and frequently associated with substantial adverse effects.
For the first time, a small device implanted in the brain has safely and accurately predicted the onset of seizures in a subset of adults whose epilepsy doesn't respond to drugs, according to a first-in-man study.
But implanting the device was not without risk: 11 device-related adverse events were noted within 4 months of implantation of the intracranial electroencephalographic monitoring system in 15 patients, Mark Cook, MBBS, of St. Vincent's Hospital, Melbourne, Australia, and colleagues wrote in an article published online by Lancet Neurology.
A total of four serious adverse events occurred during 12 months follow-up, but two of those events resolved without further complications.
As for efficacy, after 4 months, 11 of the 15 patients met criteria to move on the actual testing phase, with high likelihood performance estimate sensitivities ranging from 65% to 100%.
Epilepsy Foundation To Present Epilepsy Therapy Project Lifetime Accelerator Award To Henrik Klitgaard, Ph.D., Recognizing Contributions To New Therapies
LANDOVER, Md., April 30, 2013 /PRNewswire-USNewswire/ -- The Epilepsy Foundation announced today that Henrik Klitgaard, Ph.D., Vice President and Fellow, Neurosciences Therapeutic Area, UCB, has been named the recipient of the Epilepsy Therapy Project Lifetime Accelerator Award in recognition of his commitment and contributions to the field of epilepsy and to the people affected by it. Dr. Klitgaard will be honored at the Antiepileptic Drug and Device Trials (AED) XII Conference being held May 15-17, 2013, at the Turnberry Isle Miami Hotel, Aventura, FL.
A leading and accomplished researcher in the epilepsy community, Dr. Klitgaard has conducted antiepileptic drug discovery in the pharmaceutical industry for more than two decades, most notably contributing to the discovery and development of levetiracetam. Currently, he serves as Vice President and Fellow, Neurosciences Therapeutic Area, UCB, where he has contributed to the research and development of multiple promising new anti-epilepsy drug candidates including PPSI, seletracetam and brivaracetam.
Dr. Klitgaard was selected for the honor by an independent committee of global thought leaders and clinical investigators in epilepsy therapy discovery and development.
Former Secretary of State Hillary Rodham Clinton Honored at CURE's 15th Annual Chicago Benefit with Susan and David Axelrod
Chicago, IL - Former Secretary of State Hillary Clinton will be honored June 13th at the 15th annual Citizens United for Research in Epilepsy dinner at Navy Pier.
Secretary Clinton, who as First Lady was the keynote speaker at the inaugural CURE dinner in 1999, was the driving force behind the first White House Conference on Curing Epilepsy.
"Hillary Clinton is, in many ways, one of the founding mothers of CURE," said Susan Axelrod, CURE's chair. "Her support gave our movement for more and better research a critical boost right from the start. We are thrilled that she is returning to mark our 15th anniversary and the progress she helped make possible."
Hillary in 2016? Axelrod calls her 'first among equals'
WASHINGTON — Former Secretary of State Hillary Rodham Clinton hits Chicago on June 13 to be honored by CURE, the epilepsy research foundation — this while a new poll and the start Wednesday of a new chapter in her life are sparking even more speculation about a 2016 White House bid.
CURE — Citizens for Research in Epilepsy — was founded by President Barack Obama’s former top strategist David Axelrod, and his wife, Susan, 15 years ago; their daughter, Lauren, has epilepsy.
Clinton, then the first lady, was the draw at the group’s very first fund-raising dinner and the boost from her star power was “instrumental in getting us started,” Axelrod told me.
The June event will be at the Navy Pier Grand Ballroom and Clinton (a Chicago native: born in Edgewater Hospital, raised in Park Ridge) will deliver remarks for the CURE fund-raiser at a time when guessing about a future presidential run is the top political sport.
Since leaving the State Department, Clinton has been “an extraordinarily in demand speaker and this will be one of her early appearances. We’re thrilled to have her,” Axelrod said.
Axelrod and I spoke on Wednesday — the day after a Gallup Poll showed Clinton’s popularity soaring. Clinton’s 64 percent favorable rating was above Obama’s 55 percent and Vice President Joe Biden’s 45 percent.
Clinton on Wednesday was delivering the first of a series of highly paid speeches for private groups, with the poll and the speeches driving her political futures higher this week.
In a round of interviews before she left State, Clinton said she would be taking some time off to catch up on sleep and get in shape. Instead, she’s working on a memoir and filling her calendar with dates.
Yevgeny Berdichevsky, an assistant professor in the department of electrical and computer engineering, has been awarded a one-year, $100,000 Taking Flight award to support his research into abnormal neural circuitry—a potential cause of epilepsy.
The award is given by CURE, Citizens United for Research in Epilepsy, a 15-year-old organization that has raised more than $26 million to “lead the way to a cure for the epilepsies.” CURE uses an advisory board of more than 300 scientists to review and fund the most promising, cutting-edge projects.
Berdichevsky is the director of Lehigh’s Neural Engineering Lab, where students join him in studying neurobiology from an engineering perspective. Berdichevsky develops brain tissue cultures that are compatible with microfluidic and microelectrode devices and, using a combination of engineering and molecular approaches, studies the abnormal functions that result in epileptic seizures.
“For decades, researchers believed that epilepsy was somehow connected to imbalance of neurotransmitters in the brain,” said Berdichevsky. “As I put aside engineering for a time to learn more about the medical side of things, I began to realize that epilepsy may not just be connected to neurotransmitter levels, but rather a disorder of the neuro-circuitry itself.”
This is a relatively new notion in the field of epilepsy. The long history of medical research in this arena has focused on the idea that chemical imbalances in the brain are the cause. In recent years, however, studies have consistently determined that differences between healthy and epileptic brains may go beyond chemical transmitters..
Berdichevksy embarked upon his own research direction, looking into how an epileptic seizure begins. (A second aspect of his work is seeking a better understanding of the fundamental mechanisms of why seizures even happen.)
Ketogenic Diet offers hope of a seizure-free life to children with epilepsy
Nevin Runge was 10 months old when she had her first seizure. At 2 1/2 she had such a severe seizure that she was transported by helicopter to a local children's hospital. What followed was a cycle of drugs that often caused more harm than good, remembers her mom, April Runge, of Crystal Lake.
Nevin endured side effects that dulled her emotions or made her nerve endings scream with pain-so much so that she couldn't even bear a hug from her parents.
"We tried another drug that gave her a rash, another gave her tremors and she couldn't even hold a spoon to feed herself," April says. "We were pouring 12 medications down her throat a day."
When an EEG showed Nevin was having up to 500 seizures a day, despite all the medication, her parents decided it was time to try the Ketogenic Diet, a high-fat diet for children with epilepsy created in the 1920s that had fallen out of favor as new epilepsy drugs hit the market. But with drugs failing to be the hoped for cure-all, some doctors have begun using the diet for children with epilepsy again, often with amazing results.
In his State of the Union address, the President laid out his vision for creating jobs and building a growing, thriving middle class by making a historic investment in research and development.
Today, at a White House event, the President unveiled a bold new research initiative designed to revolutionize our understanding of the human brain. Launched with approximately $100 million in the President’s Fiscal Year 2014 Budget, the BRAIN (Brain Research through Advancing Innovative Neurotechnologies) Initiative ultimately aims to help researchers find new ways to treat, cure, and even prevent brain disorders, such as Alzheimer’s disease, epilepsy, and traumatic brain injury.
The BRAIN Initiative will accelerate the development and application of new technologies that will enable researchers to produce dynamic pictures of the brain that show how individual brain cells and complex neural circuits interact at the speed of thought. These technologies will open new doors to explore how the brain records, processes, uses, stores, and retrieves vast quantities of information, and shed light on the complex links between brain function and behavior.
In the weeks, months and years after a severe head injury, patients often experience epileptic seizures that are difficult to control. A new study in rats suggests that gently cooling the brain after injury may prevent these seizures.
“Traumatic head injury is the leading cause of acquired epilepsy in young adults, and in many cases the seizures can’t be controlled with medication,” says senior author Matthew Smyth, MD, associate professor of neurological surgery and of pediatrics at Washington University School of Medicine in St. Louis. “If we can confirm cooling’s effectiveness in human trials, this approach may give us a safe and relatively simple way to prevent epilepsy in these patients.”
CURE Grantee Uncovers Potential Cause of Childhood Epilepsy
CURE (Citizens United for Research in Epilepsy) Grantee Peter Crino, MD, PhD, has found important new evidence that the Human papillomavirus (HPV) – the most common cause of cervical cancer – may be linked to childhood epilepsy. This breakthrough discovery may lead to a definable cause and treatment for focal cortical dysplasia type IIB (FCDIIB). Dr. Crino’s work has significant ramifications for how we think about this type of childhood epilepsy and could lead to new approaches to treatment and prevention.
Specifically, the connection was identified in brain tissue from children who had surgery for FCDIIB, a form of focal malformations of cortical development (FMCD). Cortical dysplasias are malformations of the brain which occur during development and often associated with severe and difficult to treat epilepsy. Seizures in children with FMCD are often resistant to treatment with existing drugs.
CURE and HHMI Form Partnership to Foster Future Physician-Scientists in Epilepsy Research
Chicago, IL - CURE is pleased to announce an exciting new partnership with the Howard Hughes Medical Institute's Medical Research Fellows Program. CURE will provide financial support for up to three medical students each year to conduct mentored research on epilepsy.
The goal of HHMI's Medical Research Fellows Program is to increase the number of future physician-scientists and medically-trained researchers by immersing medical, dental, and veterinary students in full-time research early in their professional education. This is done before students make plans for their residency or postgraduate training so that they can consider a career as a physician-scientist, dentist- or veterinarian-scientist. The Fellows gain the research training by engaging in basic, translational or applied biomedical research for a full year at academic or nonprofit institutions.
Codey/Cunningham Bill to Improve Research on Sudden, Unexpected Death in Epilepsy Advances
TRENTON – Legislation sponsored by Senators Richard J. Codey and Sandra Bolden Cunningham that would establish a program to better educate medical examiners in the state about sudden, unexpected death in epilepsy (SUDEP) and improve research of this rare condition, was approved today by the Senate Health, Human Services & Senior Citizens Committee.
“Sudden unexpected death in epilepsy is a rare condition that affects younger or middle-aged people who die without a specific, clear cause. However, we still know relatively little about why certain people are affected,” said Senator Codey (D-Essex, Morris). “Opening the door to additional research on this condition could be the key to finding its cause, and ultimately to saving lives.”
Mild Brain Cooling After Injury Prevents Epileptic Seizures
Researchers at the University of Washington report in an upcoming issue of Annals of Neurology that mild cooling of the injured brain prevents the later development of epileptic seizures.
Epilepsy can either be genetic or acquired due to brain injury. Traumatic head injury is the leading cause of acquired epilepsy in young adults, and is often difficult to manage with available antiepileptic drugs. The mechanisms leading to the onset of epileptic seizures after brain injury are not known and there is currently no treatment to cure it, prevent it, or even limit its severity.
Neurologist Andrew Wilner, MD, discusses the first Partners Against Mortality in Epilepsy (PAME) conference with conference co-chairs Jeffrey Buchholter, MD, PhD, Pediatric Neurologist and Epileptologist at the Barrow Neurologic Institute in Phoenix, Arizona, and Gardiner Lapham, RN, MPH, Member of the Board of Directors of CURE: Citizens United for Research in Epilepsy. The meeting took place June 21-24, 2012, in Evanston, Illinois, and brought together a diverse group of scientists, clinicians, families, and others interested in advancing efforts aimed at preventing sudden death in people with epilepsy.
A laser system that targets the thalamus instantly stopped seizure-inducing signals to the cerebral cortex of rats, suggesting a new way of controlling intractable seizures in humans without injuring the vulnerable cortex.
Researchers led by John R. Huguenard, PhD, at Stanford University learned that post-thrombotic cortical stroke resulted in neuronal hyperexcitability in the thalamus, which is distant from the cortex but connected to it. To see if this process could be interrupted in real time, they developed an automated implantable system that emitted 594-nm light to the affected area as soon as seizure activity began.
Epilepsy may not be the first side effect to come to mind when you think about the after-effects of a stroke. But epileptic seizures are a relatively common result of a stroke; some studies estimate that more than 10% of stroke victims develop seizures afterward.
Despite the prevalence of epilepsy among stroke sufferers, researchers have had little idea why the two are connected. Because strokes often involve the injury or death of a region of the cortex -- the outer shell of the brain -- scientists had postulated that the function of the areas around the brain might be disrupted by the injury, leading to seizures.
White and Wilcox awarded two grants to investigate difficult-to-treat epilepsies
Brain Institute Investigator John White, Ph.D., and Professor of Pharmacology and Toxicology Karen Wilcox, Ph.D., were awarded $1.7 Million from the National Institute of Neurological Disorders and Stroke, and $300,000 from the Ben B. and Iris M. Margolis Foundation to study the roles of astrocytes in epilepsy.
There are over three million Americans with epilepsy, and for nearly one-third of them, current treatments are ineffective. Amongst the epilepsies that are difficult to treat are temporal lobe epilepsy (TLE) and viral-induced epilepsy. This is in part because the development of these types of epilepsies is not well understood.
Evidence suggests that astrocytes – long dismissed by scientists as passive support cells for neurons – undergo dramatic changes when TLE and viral-induced epilepsies are triggered in animal models. White and Wilcox will research how astrocyte dynamics influence the development of TLE and infection-induced epilepsies.
An international team of researchers, led by scientists at the University of California, San Diego and Yale University schools of medicine, have identified a form of autism with epilepsy that may potentially be treatable with a common nutritional supplement.
The findings are published in the September 6, 2012 online issue of Science.
Roughly one-quarter of patients with autism also suffer from epilepsy, a brain disorder characterized by repeated seizures or convulsions over time. The causes of the epilepsy are multiple and largely unknown. Using a technique called exome sequencing, the UC San Diego and Yale scientists found that a gene mutation present in some patients with autism speeds up metabolism of certain amino acids. These patients also suffer from epileptic seizures. The discovery may help physicians diagnose this particular form of autism earlier and treat sooner.
For years, people with seizure disorders have been stigmatized. Even today, epilepsy remains widely misunderstood, and the disease can particularly difficult for children, and for their parents. What services and treatments are available? What about research for causes and cures?
Treatments Come Slowly and Surgery Remains Risky for Epilepsy Patients
Paul Barney had his first seizure four days after his fourth birthday. By the time he was 10, his mom worried that if they didn’t get the seizures under control soon, he might lose IQ points along with his ready smile.
When Brian Manning, 11, had a seizure on the school playground – instead of in his bed as usual – his parents knew it was time for drastic action. He’d already had brain surgery once, but doctors said he might need five or six more operations. Or he could have one, to completely remove the right half of his brain.
CURE Grantee Receives Department of Defense Grant to Continue Research on TRH
Dr. Michael J. Kubek, Ph.D., who was awarded this grant, has been doing research on thyrotropin releasing hormone (TRH) for the past three decades. The Army funded international research collaboration on suicidal ideation is the latest addition to his research.
Implantable Devices Could Detect and Halt Epileptic Seizures
Epilepsy affects some 2.7 million Americans—more than Parkinson’s disease, multiple sclerosis and amyotrophic lateral sclerosis (Lou Gehrig's disease) combined. More than half of patients can achieve seizure control with treatment, yet almost a third of people with epilepsy have a refractory form of the disease that does not respond well to existing antiepileptic drugs. Nor are these patients typically helped by the one implanted device—Cyberonics' Vagus Nerve Stimulator (VNS)—that has had U.S. Food and Drug Administration approval for treatment of epilepsy since 1997.
New Study Looks at Role of Inflammation in Epilepsy
In November 2008, when he was just 6, William Moller had his first epileptic seizure, during a reading class at school. For about 20 seconds, he simply froze in place, as if someone had pressed a pause button. He could not respond to his teacher.
This is known as an absence seizure, and over the next year William, now 10, who lives with his family in Brooklyn, went from having one or two a day to suffering constant seizures. Not all were absence seizures; others were frightening tonic-clonics, also known as grand mals, during which he lost consciousness and convulsed.
New Evidence Suggests Ketogenic Diet Could Lead to New Drug Developments
A fatty diet that helps control epileptic seizures may do so by triggering a chemical change in the brain, a discovery that could lead to new treatments, according to a Harvard University study.
The diet may force a protein to switch the brain’s fuel to fat byproducts called ketones from its preferred energy, glucose, according to a study in genetically manipulated mice in the journal Neuron. Making the brain operate on ketones is known to shut down overexcited neurons that cause seizures.
This so-called ketogenic diet is used by epilepsy patients who aren’t helped by seizure-reducing drugs. The patients are only allowed a saltine cracker’s worth of carbohydrates daily, said Gary Yellen, a study author. That’s hard to do, and new treatments based on the diet’s effects in the body may lead to better control of seizures, he said.
Chicago Benefit Chair Bill Daley Discusses This Year's Event
On June 15, guests at this year's Citizens United for Research in Epilepsy fund-raiser will enjoy a musical evening with a legendary singer-songwriter. Carole King will serenade partygoers with chart-topping selections from her musical career including “It's Too Late” and “(You Make Me Feel Like) A Natural Woman,” as part of the evening in celebration of CURE’s progress in fighting epilepsy.
With a goal of raising $1 million, the uplifting soiree will aid in funding research to cure epilepsy and other neurological diseases.
MLB Teams up with Fradkin Family to "strike out" Epilepsy
The day's first seizure usually comes at 9:10 a.m.
Sarah Fradkin has it down to the minute, and she's powerless to stop it.
"I can't control it," Fradkin says. "I just go through the day, every day, and I just go with it."
As do about three million other Americans, 11-year-old Sarah has epilepsy. She was diagnosed with the disease after suffering her first seizure the day before she started first grade.
Though medication has helped others with epilepsy live a normal life, doctors have been unable to control Sarah's seizures. She's tried medicine, diets and even multiple brain surgeries in an effort to find a solution, but the daily episodes -- some of which can last up to three hours -- continue, costing her all-too-many precious moments of her otherwise active and ebullient youth.
Surgery for epilepsy is usually seen as a last resort for patients when medications do not work, and it is often delayed for many years after the failure of drug treatment. Now a randomized, controlled trial suggests that surgery as soon as possible after the failure of two antiepileptic drugs is a significantly better approach than continued medical care.
I intended this blog entry to be about comics on epilepsy, a particular branch of the so-called medical memoir. But instead it has turned out to be in part about parents blogging about their children's illness. Here's why.
Comics about illness tend to be family-centred: e.g. Sarah Leavitt's Tangles: A Story About Alzheimer's, My Mother, and Me, or Brian Fies's Mom's Cancer. Many of them track illness within an intimate group of those affected either directly or indirectly. One of the best-known long-form comics treating the subject of living with epilepsy is David B.'s Epileptic, originally published in six volumes in French under the title L'Ascension du Haut Mal (the rise of the high evil).
CURE CEO Appointed to Illinois Medical District Commission
Cook County Board President Toni Preckwinkle today appointed Carmita Vaughan, CEO of Citizens United for Research in Epilepsy (CURE) to the Illinois Medical District Commission.
Preckwinkle cited Vaughan’s strong managerial experience, her familiarity with medical issues and healthcare, and her deep-rooted commitment to service as her main reasons for her selection for this important position.
“Ms. Vaughan’s dedication to medical research, public health and compassionate service will serve her well on the IMDC,” said President Preckwinkle. “She will be a strong voice for improving the delivery of health care in our communities and continuing to strengthen the Illinois Medical District’s role in Cook County’s economy.”
New York, February 9, 2012 – A groundbreaking study published in Elsevier's Epilepsy & Behavior provides evidence in mouse model that drugs known as Selective Serotonin Reuptake Inhibitors (SSRIs; one category of antidepressants) may reduce the risk of Sudden Unexpected Death in Epilepsy (SUDEP).
SUDEP is estimated to be the cause of death in up to 17% of patients with epilepsy who die from their condition. Evidence for cardiac and respiratory causes of SUDEP has been presented, but no effective prevention of SUDEP has yet been developed.
Several studies have proposed that DBA mouse models of seizure-induced sudden death that are due to respiratory arrest may be useful models for respiratory-related causes of SUDEP. In these models, the generalized convulsive seizure is induced by acoustic stimuli, and the incidence of death after the seizure can be greatly reduced or prevented by providing rapid respiratory support.
When aspiring singer Scott Mannis was 17 years old, he began periodically losing feeling in the left side of his body, specifically in his leg. It took three years for doctors to diagnose his condition as a rare form of epilepsy, whose symptoms can be minimized, but for which there is no cure.
But Mannis, now a 24-year-old astrophysics student at Columbia University, found a temporary reprieve through music. "By 2008, the seizures got bad enough that I wasn't able to walk without falling," he tells Billboard. "The only time I didn't have them was when I was singing."
Irvine, Calif., June 27, 2011 – UC Irvine and French researchers have identified a central switch responsible for the transformation of healthy brain cells into epileptic ones, opening the way to both treat and prevent temporal lobe epilepsy.
Epilepsy affects 1 to 2 percent of the world’s population, and TLE is the most common form of the disorder in adults. Among adult neurologic conditions, only migraine headaches are more prevalent. TLE is resistant to treatment in 30 percent of cases.